international marketing mohamed badrawy fortune 500

8/6/2019 International Marketing Mohamed Badrawy Fortune 500

1/29

Fortune 500

By: mohamed badrawy


2/29

Cl assify C ompanies By C ountryCountry # Country # Country #

1-AUSTRALIA 8 14-INDIA 8 27-SOUTH KOREA 10

2-AUSTRIA 3 15-IRELAND 2 28-SPAIN 10

3-BELGIUM 5 16-ITALY 11 29-SWEDEN 5

4-BELGIUM/NETHERLAND

1 17-JAPAN 71 30-SWITZERLAND 15

5-BRAZIL 7 18-LUXEMBOURG 1 31-TAIWAN 8

6-BRITIAN 29 19-MAYLASIA 1 32-THAILAND 1

7-BRITIAN/NETHERLAND

1 20-MEXI C O 2 33-TURKEY 1

8-C ANADA 11 21-NETHERLANDS 13 34-U.S 139

9-C HINA 46 22-NORWAY 1 35-VENEZUELA 1

10-DENMARK 2 23-POLAND 1

11-FINLAND 1 24-RUSSIA 6

12-FRAN C E 39 25-SAUDI ARABIA 1

13-GERMANY 37 26-SINGAPORE 2


3/29

Cl assify By Regions

REGION N o. of Companies

AMERI C AS 160

ASIA PA C IFIC & AUSTRALIA 157

EUROPE 183


4/29

AMERI C AS

COUNTRY NO . OF COMPANIES

BRAZILC ANADAMEXIC OU.SVENEZUELA

71121391


5/29

ASIA PA C IFICCOUNTRY NO . OF COMPANIES

AUSTRALIAC HINAINDIA

JAPANMALAYSIASAUDI ARABIASINGAORESOUTH KOREATAIWAN

THAILANDTURKEY

8468

71112108

11


6/29

EUROPECOUNTRY NO . OF

COMPANIESCOUNTRY NO . OF

COMPANIES

AUSTRIA 3 ITALY 11

BELGIUM 5 LUXEMBOURG 1

BELGIUM/NETH

ERLANDS

1 NETHERLANDS 13

BRITAN 29 NORWAY 1

BRITAIN/NETHERLANDS

1 POLAND 1

DENMARK 2 RUSSIA 6

FINLAND 1 SPAIN 10

FRAN C E 39 SWEDEN 5

GERMANY 37 SWITZERLAND 15

IRELAND 2


7/29

Cl assify By IndustryIndustry % change from

2007

Industry % change

from 2007Food Production 48.8 Telecommunications 9.8

Energy 34.9 Household and Personal Products 9.6

Petroleum Refining 27.8 Food and Drug Stores 9

Diversified Financials 27.1 Building Materials, Glass 7.1

Metals 25.5 Banks: Commercial and Savings 7

Engineering, Construction 22.4 Aerospace and Defense 6.8

Mining, Crude-Oil Production 21.2Network and Other CommunicationsEquipment 6.2

Utilities 19.4 Wholesalers: Health Care 5.8

Beverages 19.3 Mail, Package, and Freight Delivery 5.7

Trading 15.9 Entertainment 5.5

Shipping 14.3 Pharmaceuticals 4.9

Chemicals 13.9 General Merchandisers 4.8

Industrial Machinery 13.3 Computers, Office Equipment 4.1

Specialty Retailers 12.5 Airlines 1.9

Food Consumer Products 10.7 Electronics, Electrical Equip. 0.6

Telecommunications 9.8 Insurance: Property and Casualty (Stock) -2.3Household and PersonalProducts 9.6 Insurance: Life, Health (stock) -2.4

Food and Drug Stores 9 Motor Vehicles and Parts -3.6

Health Care: Insurance andManaged Care 8.4


8/29

Pharmaceutica ls

y Top 5 companies:

1-Johnson & Johnson

2-Pfizer

3-Ga laxoSmithK line

4-Roche Group5-Sanofi-Aventis


9/29

MISSION ( C REDO) :Our C redo We be lieve our first responsibi lity is to the doctors, nurses and


10/29

We must provide competent management, and their actions mustbe just and ethica l. We are responsib le to the communities in

which we live and work and to the wor ld community as we ll. Wemust be good citizens-support good works and charities and bear our fair share of taxes. We must encourage civic improvements

and better hea lth and education. We must maintain in good order the property we are privi leged to use, protecting the environment

and natura l resources. Our fina l responsibi lity is to our stockho lders. Business must make a sound profit. We mustexperiment with new ideas. Research must be carried on,

innovative programs deve loped and mistakes paid for. Newequipment must be purchased, new faci lities provided and new

productslaunched. Reserves must be created to provide for adverse times. When we operate according to these princip les, thestockho lders shou ld rea lize a fair return.


11/29

P roduct M ix:

Three segments:-

C onsumer

Pharmaceutica lMedica l Devices and Diagnostics C onsumer


12/29

Consumer P roducts:

1) Baby C are

2) Skin & Hair C are

3) Wound C are & Topica l

4) Ora l Hea lth C are

5) Womens Hea lth

6) Over-the-counter Medicines

7) Nutritiona ls

8) Vision C are


13/29

13) Medica l Diagnostics14) B lood Screening15) Cl inica l Lab Equipment

16) Diagnostic Tests & Molecu

lar Diagnostics

17) Vision C are18) Genera l Surgery19) Bariatric Surgery Of Obesity20) Uro logic Surgery21) Hernia Surgery22) Womens Hea lth & Uro logy23) P lastic Surgery24) Surgica l Instruments and InfectionPrevention

Medica l Devices & Diagnostics1) Orthopaedics2) Imp lants3) Joint Rep lacements4) Sports Medicine and trauma5) Heart & Vascu lar Disease6) C oronary Artery Disease7) Periphera l Vascu lar AndObstructive Disease8) Neuro logica l Disease9) Arrhythmias10) Diabetes11) Se lf-Measured B lood G lucoseMonitors12)Insu lin De livery Devices


14/29

The Pharmaceutica l segment's broad portfo lio focuses onunmet medica l needs across severa l therapeutic areas:onco logy; infectious disease; immuno logy;neuroscience; cardiovascu lar and metabo lism. Itinc ludes products in the anti-infective, antipsychotic,cardiovascu lar, contraceptive, dermato logy,gastrointestina l, hemato logy, immuno logy, neuro logy,onco logy, pain management, uro logy and viro logy

fields. Be low are some of our main products.


15/29

OUR ENDURING STRENGTHWITH THE C HALLENGES OF 2010, ANDWITHIN THE C ONTEXT OF OUR 125TH ANNIVERSARY IN 2011, WE AREREMINDED MORE THAN EVER OF OUR HERITAGE. UNWAVERINGC OMMITMENT TO THE PRIN C IPLES EMBODIED IN OUR C REDO AND AN

APPRE C IATION FOR THE ELEMENTS OF OUR OPERATING MODEL ARE AS STRONG TODAY AS AT ANY TIME IN OUR HISTORY.WE ARE NOTPERFE C T; W E WILL MAKE MISTAKES. AND WHEN WE DO, WE HOLDOURSELVES A CC OUNTABLE TO C ORRE C T THEM. THAT

ACC OUNTABILITY IS INHERENT IN OUR C REDO. ITS TENETS DEMAND ASPE C IAL LEVEL OF RESPONSIBILITY FIRST TO PATIENTS ANDC USTOMERS, THEN TO OUR EMPLOYEES, OUR C OMMUNITIES ANDOUR SHAREHOLDERS. OUR C REDO REMAINS OUR NORTHSTAR.ANOTHER ENDURING STRENGTH IS THE C HARAC TER OF THEPEOPLE OF JOHNSON & JOHNSON. DESPITE DIVERSE BUSINESSES,WE ARE UNITED BY AN EXTRAORDINARY BONDA C OMMITMENT TOC ARING FOR ONE PERSON AT A TIME AND TOU C HING THE WORLDORIGINATING FROM OUR C REDO VALUES. IT IS A QUIET SENSE OFPURPOSE FO C USED AROUND THE LIVES WE AFFE C T, THE FAMILIES

AND C HILDREN WE TOU C H, AND THE PROFESSIONALS WHO SUPPORTTHEIR HEALTH.OUR PRODU C TS, OUR PIPELINE AND OUR GLOBALPRESEN C E MAKE US STRONG AS A C OMPANY. OUR PEOPLE AND OURC REDO SET US APART.


16/29

P fizer M ission S tatement:

" We will become the world's most valued company to patients, customers,colleagues, investors, business partners, and the communities where we work and live."


17/29

P roduct M ix

1)Human Hea lth

a) OT C Productsb) Prescription Products

2) Anima l Hea lth


18/29

To maximize new opportunities in biomedica l research, and bring more innovativemedicines to more patients more quick ly, Pfizer has created two distinctresearch organizations. The PharmaTherapeutics Research & Deve lopmentGroup focuses on the discovery of sma ll mo lecu les and re lated moda lities;and The BioTherapeutics Research & Deve lopment Group focuses on large-mo lecu le research, inc luding vaccines.Pfizer has a lso deve loped an enhancedcommercia l operating structure. Pfizer has nine diverse hea lth carebusinesses: Primary C are, Specia lty C are, Onco logy, Emerging Markets,Estab lished Products, C onsumer Hea lthcare, Nutrition, Anima l Hea lth andC apsuge l. Each of these businesses is led by an executive with c lear accountabi lity for resu lts - from product deve lopment fo llowing proof of concept to providing access to patients and through to the end of theproduct's life cyc le. The businesses are provided with the resources to pursueattractive growth opportunities and to de liver benefits to a ll who re ly on usaround the wor ld.With this structure, we are ab le to rapid ly capita lize onopportunities to advance our business by increasing support for successfu l new medicines, forging partnerships with key customers, entering into co-promotion and licensing agreements, investing in new techno logies to addva lue to our core product offerings, and acquiring new products and servicesfrom outside the company.


19/29

MISSION :

The pharmaceutica l industry is experiencing a time of unprecedentedcha llenge. Patent expiries, regu latory issues and increased pressuresfrom hea lthcare providers have combined to create an environmentwhere our sector is associated with lower growth and higher risk. We areaddressing these cha llenges through three key strategic priorities thatwe be lieve wi ll transform GSK into a company that de livers more growth,less risk and an improved financia l performance.


20/29

Product Mix

1-Prescription medicines

2-Consumer Healthcare

3-Vaccines

4-Stieffel


21/29


22/29

Roc h e maintains open and h onest relations h ips wit h our s h are h olders, prospectiveinvestors and t h e wider investment community. Th e role of Investor Relations is tomanage t h ese relations h ips efficiently, transparently and consistently in accordancewit h company polices and relevant securities rules and laws. Our goals are to:

Provide timely, relevant, consistent and accurate information to all shareholdersand prospective investors to aid them in assessing the value of Roche and to makeinformed investment decisions

Facilitate dialogue between Roche management and the investment community

Achieve a fair valuation of Roche by the financial markets


23/29

A) Ph armaceuticals

1- Oncology2-Virology3-Inflammation4-Metabolic Disorders5-Central Nervous System

B) Solutions for Diagnostics

C) Products for Researc h ers


24/29

Where we are today Today Roche ranks among the wor lds

leading hea

lthcarecompanies and has two strong core businesses: diagnostics and pharmaceutica ls.

Serving Patients and C ustomers Roches prime objective is to identify and meet thepatients and customers needs. This imp lies so lving their prob lems and anticipatingtheir future needs by maintaining c lose contact with them and listening to what theysay. At Roche we focus our resources on two research intensive businesses:

pharmaceuticals and diagnostics. Within these businesses we priorities those areasof significant unmet need where we have the expertise to make a difference. Our

aim is to deve lop new and improved drugs, diagnostic tests and services offeringsignificant benefits over existing options. Focusing on Innovation By innovation wemean the creation and commercia lization of medica lly differentiated products andservices that lead to a tangib le improvement to the hea lth, qua lity and length of patients lives. As a research-focused company we exp loit the latest discoveries andtechno logies to deve lop our products. This is why Roche invested over 9 bi llionSwiss francs in 2010 on research and deve lopment. Roche continues itslongstanding tradition of working in a lliances with some of the most forward- lookingand techno logica lly advanced companies in the wor ld. Roche invests heavi ly inbiotechno logy and is the wor lds largest biotechno logy company.


25/29

Where we re going Personalized Healthcare Two patients can have the same diagnosisyet respond in different ways to the same medicine. One patient may be helped bytreatment, while the other experiences unwanted side effects without the desiredclinical benefit. Some of this variability is due to genetic and other biological differencesbetween patients. The idea of personalized healthcare is to use insights into these

differences at the molecular level to develop treatments and tests tailored to the needsof specific patient populations. This has enormous potential to make healthcare better,safer and more cost-effective. It will be a while before this potential is fully realized, butthe market is clearly shifting away from one size fits all products. Roche is a drivingforce behind this trend and already has several personalized healthcare products on themarket. One important aspect of personalizing medicine is the close interaction

between pharmaceuticals and diagnostics. The fact that we are leaders in both theseareas is a source of competitive advantage when it comes to meeting the healthcarechallenges of the future.


26/29

As a company, AstraZeneca US is committed to a mission of improving h umanh ealt h .

The people of AstraZeneca are dedicated to :

Discovering, developing, and delivering innovative, meaningful medicines andother healthcare solutions that help enrich the lives of patients, as well as theirfamilies and communities

Putting the health of patients first by providing educational programs, resources,and tools designed to help empower and inform

Creating a challenging and rewarding work environment that inspires ouremployees


27/29

Seven major t h erapy areas Sanofi-aventis focuses its activities on:

Cardiovascular medicine

ThrombosisOncologyinternal medicinemetabolic disordersdiseases of the central nervous systemvaccines


28/29


29/29

Thank You

international marketing mohamed badrawy fortune 500

Documents